These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 17435382)

  • 21. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
    Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
    N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis.
    Adeboyeku D; Scott S; Hodson ME
    J Cyst Fibros; 2006 Dec; 5(4):261-3. PubMed ID: 16807142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
    Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa.
    Béghin L; Michaud L; Loeuille GA; Wizla-Derambure N; Sayah H; Sardet A; Thumerelle C; Deschildre A; Turck D; Gottrand F
    Pediatr Pulmonol; 2009 May; 44(5):464-71. PubMed ID: 19360849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
    Wertz DA; Chang CL; Stephenson JJ; Zhang J; Kuhn RJ
    J Med Econ; 2011; 14(6):759-68. PubMed ID: 21942462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhaled antibiotic therapy in cystic fibrosis].
    Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.